查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1869869

血尿治療市場規模、佔有率和趨勢分析報告：按治療類型、類型、地區和細分市場預測（2025-2033 年）

Hematuria Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Pharmacotherapy, Procedural / Interventional Therapies, Adjunctive / Supportive Therapies), By Type, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

血尿治療市場摘要

2024年全球血尿治療市場規模估計為10.873億美元，預計2033年將達到14.269億美元。

預計從 2025 年到 2033 年，該市場將以 3.1% 的複合年成長率成長。泌尿系統護理是推動市場成長的主要因素，而復發性尿道感染、膀胱癌和尿道結石的盛行率不斷上升，以及老年人口的不斷成長，都為市場成長提供了支撐。

血尿是膀胱癌最常見且最重要的早期臨床症狀，使其成為一種負擔沉重的疾病，需要大量的診斷和治療資源。此外，全球膀胱癌病例的不斷增加預計將推動整體市場成長。在美國，美國癌症協會預測2025年將新增84,870例膀胱癌病例，反映出發生率穩定，且診斷性膀胱鏡檢查仍是主要依賴手段。由於大多數膀胱癌需要持續後續觀察，包括重複膀胱鏡檢查和風險適應性膀胱內治療，因此病例數量的增加正在推動血尿治療行業的發展。

此外，尿道感染（UTI）發生率的上升導致陣發性血尿就診量增加，經驗性抗生素的使用也隨之增多，從而推高了對緊急評估的需求，並對快速照護現場診斷提出了更高的要求。新的快速診斷方法縮短了病原體鑑定時間，並透過縮短診斷時間直接影響血尿的治療路徑。

尿道結石及其症狀是肉眼血尿的重要非腫瘤性原因，通常需要內視鏡泌尿外科治療（內視鏡泌尿外科手術、經皮腎鏡取石術）和影像學檢查。雖然一些地區的年齡調整發生率有所下降，但絕對病例數和新發病例數在許多地區仍在增加。此疾病的特徵是症狀明顯且復發率高，尤其影響20至54歲的人群，對醫療保健系統帶來沉重負擔。這顯示許多地區結石疾病的年齡調整盛行率顯著偏高且呈上升趨勢，導致急診和擇期手術數量增加。由於結石和血尿就診人數不斷增加，診斷性膀胱鏡檢查仍然是泌尿系統最常進行的檢查之一。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 血尿治療市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 血尿治療市場分析工具
    • 產業分析—波特五力分析
    • PESTEL 分析

第4章 血尿治療市場：治療類型估算與趨勢分析

  • 治療類型細分儀表板
  • 血尿治療市場：治療類型差異分析
  • 全球血尿治療市場規模及趨勢分析（依治療類型分類，2021-2033 年）
    • 藥物治療
    • 治療/干預
    • 輔助性治療/支持性護理

第5章 血尿治療市場：類型估算與趨勢分析

  • 類型細分儀表板
  • 血尿治療市場：類型差異分析
  • 全球血尿治療市場規模及趨勢分析（按類型分類）（2021-2033 年）
    • 品牌
    • 非專利的

第6章 血尿治療市場：區域估算與趨勢分析

  • 區域市場概覽
  • 2024 年及 2030 年區域市佔率分析
  • 按地區分類的血尿治療市場：重點
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭情勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
  • 公司簡介
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson &Johnson and its affiliates
    • Merck &Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
Product Code: GVR-4-68040-783-3

Hematuria Treatment Market Summary

The global hematuria treatment market size was estimated at USD 1,087.3 million in 2024 and is projected to reach USD 1,426.9 million by 2033, growing at a CAGR of 3.1% from 2025 to 2033. The market is driven by urological care and sustained by the growing prevalence of recurrent urinary tract infections, bladder cancer, and urolithiasis, alongside an expanding geriatric population.

Hematuria is the most common and vital early clinical sign for bladder cancer, which is a high-burden disease that requires extensive diagnostic and therapeutic resources. Moreover, the increasing incidence of bladder cancer cases globally is expected to drive the overall market growth. In the U.S., the American Cancer Society projects 84,870 new cases in 2025, reflecting stable incidence and continued reliance on diagnostic cystoscopy. Given that most bladder cancers require ongoing surveillance through repeated cystoscopy and risk-adapted intravesical therapy, rising case volumes drive the hematuria treatment industry.

Furthermore, rising urinary tract infection (UTI) incidence increases episodic hematuria presentations and empirical antibiotic use, which drives urgent evaluation demand and creates pressure for faster, point-of-care diagnostics. New rapid diagnostics have shortened pathogen identification, directly affecting hematuria treatment pathways by shortening time-to-diagnosis.

Urolithiasis prevalence and symptomatic stone events are important non-neoplastic causes of visible hematuria and often require definitive endourologic care (URS, PCNL) or imaging triage. Although some age-standardised rates have declined, absolute case counts, and new presentations have risen in many regions. It is characterized by symptoms and a high likelihood of recurrence and has created a considerable burden on the healthcare system, especially affecting individuals aged 20 to 54. This indicates substantial age-standardized incidence of stone disease and rising rates in many regions, which raises emergency and elective procedure volumes. Diagnostic cystoscopy remains among the most frequently performed urology procedures, so rising stone and hematuria referrals drive the industry.

Global Hematuria Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hematuria treatment market report based on treatment type, type, and region:

  • Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmacotherapy
  • Procedural / Interventional Therapies
  • Adjunctive / Supportive Therapies
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Branded
  • Generic
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment type
    • 1.2.2. Type
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment type outlook
    • 2.2.2. Type outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hematuria Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Hematuria Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Hematuria Treatment Market: Treatment Type Estimates & Trend Analysis

  • 4.1. Treatment Type Segment Dashboard
  • 4.2. Hematuria Treatment Market: Treatment Type Movement Analysis
  • 4.3. Global Hematuria Treatment Market Size & Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
    • 4.3.1. Pharmacotherapy
      • 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.2. Procedural / Interventional Therapies
      • 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.3. Adjunctive / Supportive Therapies
      • 4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Hematuria Treatment Market: Type Estimates & Trend Analysis

  • 5.1. Type Segment Dashboard
  • 5.2. Hematuria Treatment Market: Type Movement Analysis
  • 5.3. Global Hematuria Treatment Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
    • 5.3.1. Branded
      • 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.2. Generic
      • 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Hematuria Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Hematuria Treatment Market by Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Germany
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.3. France
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.4. Italy
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.5. Spain
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.6. Denmark
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Regulatory framework/reimbursement structure
      • 6.5.7.3. Competitive scenario
      • 6.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key country dynamics
      • 6.5.8.2. Regulatory framework/reimbursement structure
      • 6.5.8.3. Competitive scenario
      • 6.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.4. South Korea
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.6. Thailand
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.2. Mexico
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.3. UAE
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key country dynamics
      • 6.8.4.2. Regulatory framework/reimbursement structure
      • 6.8.4.3. Competitive scenario
      • 6.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company heat map analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. AstraZeneca
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Bristol-Myers Squibb Company
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. F. Hoffmann-La Roche Ltd.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Johnson & Johnson and its affiliates
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Merck & Co., Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Novartis AG
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Pfizer Inc.
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Sun Pharmaceutical Industries Ltd.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiativesa

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global hematuria treatment market, by region, 2021 - 2033 (USD Million)
  • Table 3 Global hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 4 Global hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 5 North America hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 6 North America hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 7 North America hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 8 U.S. hematuria treatment, by treatment type, 2021 - 2033 (USD Million)
  • Table 9 U.S. hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 10 Canada hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 11 Canada hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 12 Europe hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 13 Europe hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 14 Europe hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 15 Germany hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 16 Germany hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 17 UK hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 18 UK hematuria treatment market, by drug, 2021 - 2033 (USD Million)
  • Table 19 France hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 20 France hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 21 Italy hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 22 Italy hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 23 Spain hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 24 Spain hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 25 Denmark hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 26 Denmark hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 27 Sweden hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 28 Sweden hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 29 Norway hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 30 Norway hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 31 Asia Pacific hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 32 Asia Pacific hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 33 Asia Pacific hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 34 Japan hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 35 Japan hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 36 China hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 37 China hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 38 India hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 39 India hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 40 South Korea hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 41 South Korea hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 42 Australia hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 43 Australia hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 44 Thailand hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 45 Thailand hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 46 Latin America hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 47 Latin America hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 48 Latin America hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 49 Brazil hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 50 Brazil hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 51 Mexico hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 52 Mexico hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 53 Argentina hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 54 Argentina hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 55 MEA hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 56 MEA hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 57 MEA hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 58 South Africa hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 59 South Africa hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 60 Saudi Arabia hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 62 UAE hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 63 UAE hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 64 Kuwait hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 65 Kuwait hematuria treatment market, by type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Hematuria treatment market: market outlook
  • Fig. 9 Hematuria treatment competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Hematuria treatment market driver impact
  • Fig. 14 Hematuria treatment market restraint impact
  • Fig. 15 Hematuria treatment market strategic initiatives analysis
  • Fig. 16 Hematuria treatment market: treatment type movement analysis
  • Fig. 17 Hematuria treatment market: treatment type outlook and key takeaways
  • Fig. 18 Pharmacotherapy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 Procedural /Interventional therapies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Adjunctive / Supportive therapies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Hematuria treatment market: type movement analysis
  • Fig. 22 Hematuria treatment market: type outlook and key takeaways
  • Fig. 23 Branded market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Generic market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Global hematuria treatment market: Regional movement analysis
  • Fig. 26 Global hematuria treatment market: Regional outlook and key takeaways
  • Fig. 27 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)